Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
P 2 (1)

Trial Status

Completed1
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT07200882Not Yet RecruitingPrimary

What is the Impact of TKI on Thyroid Function in CML Patients?

NCT01334060Phase 2Completed

WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation

Showing all 2 trials

Research Network

Activity Timeline